-
Osimertinib Plus Chemo Significantly Extends Survival for Patients With Lung Cancer
16 Sep 2025 16:39 GMT
… of smoking, but EGFRm lung cancers present more in atypical … with other types of lung cancers, the immune systems in … mg/m2) or carboplatin (AUC5) every 3 weeks for … html
2. Lung Cancer Foundation of America. EGFR. Lung Cancer Foundation of America …
-
Cisplatin/Carboplatin Plus Etoposide Yield Similar Real-World Efficacy in ES-SCLC
17 Sep 2025 01:13 GMT
… either cisplatin and etoposide or carboplatin and etoposide achieved similar survival … either [cisplatin and etoposide] or [carboplatin and etoposide] are appropriate [first … for the Study of Lung Cancer World Conference on Lung Cancer 2025; September 6 …
-
Bispecific Antibody Improves PFS in EGFR-Mutated Lung Cancer
10 Sep 2025 21:29 GMT
… EGFR-mutated non-small cell lung cancer (NSCLC) who have progressed on … at the World Conference on Lung Cancer (WCLC) 2025.
The study demonstrated … (500 mg/m²) and carboplatin every 3 weeks for four …
-
FLAURA2 phase III trial of AstraZeneca's Tagrisso plus chemotherapy demonstrated a median overall survival in EGFR─mutated advanced lung cancer
09 Sep 2025 10:38 GMT
… EGFRm) non-small cell lung cancer (NSCLC).
These results presented … . Lung cancer is broadly split into small cell lung cancer or … 75mg/m2) or carboplatin (AUC5) every three weeks … improvements for people with lung cancer, including and beyond treatment …
-
AstraZeneca Lung Cancer Combo Extends Patient Survival By Years In Key Study
08 Sep 2025 18:12 GMT
… (Stage IV) non-small cell lung cancer (NSCLC) whose tumors have EGFR … of chemotherapy plus cisplatin or carboplatin every three weeks for four …
-
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
08 Sep 2025 15:00 GMT
… Lung Cancer in Barcelona. “Small cell lung cancer is the most aggressive type of lung cancer … small cell lung cancer (Cohort 1 … + chemotherapy (etoposide+carboplatin) for four cycles … Lung Cancer
Small cell lung cancer (SCLC) accounts for 15% of all lung cancer …
-
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer
06 Sep 2025 09:08 GMT
… Lung Cancer (IASLC) 2025 World Congress on Lung Cancer … Small Cell Lung Cancer
Worldwide, lung cancer is one … characteristics of lung cancers harboring EGFR … Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer …
-
Emerging Targets in Non-Small Cell Lung Cancer
06 Sep 2025 06:12 GMT
… lung cancer (NSCLC) represents approximately 85% of all lung cancer … non-small cell lung cancer: molecular mechanisms and … carboplatin alone or with bevacizumab for non-small-cell lung cancer … advanced non-small cell lung cancer. Lung Cancer. 2023;182:107291. …
-
Sunvozertinib Monotherapy in Advanced Lung Adenocarcinoma with EGFR Exon 20 Insertion and High PD-L1 Expression: A Case Report
18 Sep 2025 06:58 GMT
… adenocarcinoma originating from the lung. Tumor purity was assessed by … ),35 amivantamab plus chemotherapy (carboplatin-pemetrexed) for advanced EGFR exon … Tumor Microenvironment in EGFR-Mutant Lung Cancer: opportunities and Challenges. Biomedicines. …
-
Sunvozertinib Brings Changes in Non-Small Cell Lung Cancer Treatment
11 Aug 2025 19:10 GMT
… cell lung cancer (NSCLC) and small cell lung cancer.1 NSCLC … accounts for around 85% to 90% of lung cancers … Carcinoma
Amivantamab-vmjw plus carboplatin/pemetrexed
Second- … Metastatic non-small-cell lung cancer: ESMO Clinical Practice …
About
© 1995-2025